Track record · closed signal

Merck & Company Inc (MRK) — closed signal from July 15, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on October 13, 2026 — +15.2% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$119.58 – $122.55Entry zone — fair-value band

$123.24Published — price the day we called it

$129.87Target — the price the thesis aimed for

$156.00Peak — highest point inside the window, not a realized return

$141.98Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 2 days.

At window close

+15.2%

realized, from the publication price to the last close inside the window

Peak gain

+26.6%

peak, from the publication price — not a realized return

S&P 500, same window

+3.3%

SPY over the identical days, dividend-adjusted

Window close

$141.98

last close inside the window, ended October 13, 2026

Peak price

$156.00

peak on August 25, 2026 — not a realized return

Days to target

The thesis — published July 15, 2026

Predicted growth

+6%

over the measurement window

Target price

$129.87

the price the thesis aimed for

Entry zone

$119.58 – $122.55

the fair-value band we waited for

Price at publication

$123.24

published July 15, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is a steady healthcare company that just got two positive developments for its Keytruda cancer drug: broader approval for bladder cancer and a strong late-stage result in endometrial cancer. These can lift forecasts and sentiment in the next few months. However, slow sales growth, dropping profits, a pricey valuation, sizable debt, and weak market momentum probably limit a big re-rating despite the good clinical news.

Primary drivers

Broader approval for Keytruda in bladder cancer, boosting sales prospects
Strong late-stage result in endometrial cancer that supports future use
Reliable earnings performance and steady demand for core products
Sluggish sales growth, heavy debt, and a high valuation weigh on upside

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals